Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018222718) TREATMENT OF LAG-3 POSITIVE TUMORS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/222718 International Application No.: PCT/US2018/035134
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
G01N 33/574 (2006.01) ,A61K 39/395 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
BRISTOL-MYERS SQUIBB COMPANY [US/US]; Rt. 206 & Province Line Road Princeton, New Jersey 08543, US
Inventors:
NOVOTNY, James; US
LONBERG, Nils; US
HEDVAT, Cyrus; US
CLYNES, Raphael; US
LOCKE, Darren; US
COGSWELL, John P.; US
JACKSON, Jeffrey; US
HARBISON, Christopher; US
EDWARDS, Robin; US
Agent:
CALVO, Paul A.; US
BANOWIT, Donald R.; US
BEZOS, Salvador M.; US
BODENSTEIN, Matthew; US
CAMARCE, Christian; US
CIMBALA, Michele A.; US
COLLER III, Richard D.; US
CONKLIN, Kyle; US
CORNWELL, David K.S.; US
COVERT, John M.; US
DURKIN, Tracy-Gene G.; US
EISENBERG, Jason D.; US
ELLISON, Eldora L.; US
ESMOND, Robert W.; US
FEATHERSTONE, Donald J.; US
FRUEAUF, Jeremiah B.; US
GAJEWSKI, Daniel; US
GILLENTINE, Marsha Rose; US
GOLDSTEIN, Jorge A.; US
HELVEY, Jeffrey T.; US
HICKS, Ross; US
HOLOUBEK, Michelle K.; US
JACKMAN, Peter A.; US
KIM, Ji-Eun; US
LEE, Michael Q.; US
LONGSWORTH, Gaby L.; US
MESSINGER, Michael V.; US
MILLONIG, Robert C.; US
MUTSCHELKNAUS, Joseph; US
NANNENGA-COMBS, Bonnie; US
POWERS, Trey; US
RAY, Michael B.; US
RYGIEL, Mark W.; US
SHEA JR., Timothy J.; US
SOKOHL, Robert E.; US
SPECHT, Michael D.; US
STEFFE, Eric K.; US
STERLING, Deborah A.; US
STERNE, Robert Greene; US
Priority Data:
62/512,64830.05.2017US
62/513,81301.06.2017US
62/555,17607.09.2017US
62/582,17806.11.2017US
Title (EN) TREATMENT OF LAG-3 POSITIVE TUMORS
(FR) TRAITEMENT DE TUMEURS POSITIVES POUR LAG-3
Abstract:
(EN) The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.
(FR) L'invention concerne une méthode de traitement d'une tumeur chez un patient humain comprenant (i) l'identification d'un patient comme présentant une tumeur positive pour LAG -3 et (ii) l'administration au patient d'un inhibiteur de la voie PD-1, d'une combinaison d'un inhibiteur de la voie PD1 et d'un inhibiteur des points de contrôle immunitaires, d'une combinaison d'un inhibiteur de LAG-3 et d'un inhibiteur de la voie PD-1, ou d'un anticorps anti-CTLA4. Dans certains modes de réalisation, la méthode comprend en outre l'identification du patient comme présentant une tumeur positive pour PD-L1 positive pour LAG-3. Dans certains modes de réalisation, l'inhibiteur de LAG-3 est un anticorps anti-LAG-3 et l'inhibiteur de la voie PD-1 est un anticorps anti-PD-1. Les méthodes de l'invention peuvent améliorer les taux de réponse à un traitement par un inhibiteur de la voie PD-1, par une combinaison d'un inhibiteur de la voie PD-1 et d'un inhibiteur des points de contrôle immunitaires, ou par une combinaison d'un inhibiteur de LAG-3 et d'un inhibiteur de la voie PD-1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)